Photopheresis in HIV-1 infected patients utilizing benzoporphyrin derivative (BPD) verteporfin and light

Current HIV Research

Volumn 6, Issue 2, 2008, Pages 152-163

  Bernstein, Zale P ^a   Dougherty, Thomas ^a   Gollnick, Sandra ^a   Schwartz, Stanley A ^b   Mahajan, Supriya D ^b   Kepner, James ^a   Sumlin, Adam ^a   Stewart, Carleton ^a   Wallace, Paul ^a   Adal, Adaffaras ^a   Walder, Harold ^d   Poiesz, Bernard ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^d Therakos   (United States)

Author keywords

Benzoporphyrin; Chemokine; Granzyme; HIV; Photopheresis

Indexed keywords

AMPRENAVIR; BENZOPORPHYRIN DERIVATIVE; CHEMOKINE; CYTOKINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; TENOFOVIR DISOPROXIL; VERTEPORFIN; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PORPHYRIN;

APOPTOSIS; BLOOD PRESSURE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FREE SYSTEM; CELL VIABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VIVO STUDY; LEUKOCYTE CULTURE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOCYTOPENIA; NONHUMAN; PROTEIN EXPRESSION; PULSE RATE; PUVA; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TEMPERATURE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS PARTICLE; VITAL SIGN; ARTICLE; CELL SURVIVAL; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LEUKOCYTE; LIGHT; LYMPHOCYTE COUNT; METHODOLOGY; VIROLOGY;

ANTI-HIV AGENTS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES; LIGHT; LYMPHOCYTE COUNT; PHOTOPHERESIS; PORPHYRINS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL LOAD;

EID: 41249087693     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208783885001     Document Type: Review

References (43)

1. Kilby JM. Human immunodeficiency virus pathogenetis: insights from studies of lymphoid cells and tissues. Clin Infect Dis 2001; 33(6): 873-884.
2. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature 2001; 410: 980-987.
3. Ickovics JR, Meade CS. Adherence to HAART among patients with HIV: breakthroughs and barriers. AIDS Care 200; 14(3): 309-318.
4. Rubegni P, DeAloe G, Fimiani M. Extracorporeal photochemotherapy in long-term treatment of early stage cutaneous T-cell lymphoma. Br J Derm 2000; 143(4): 894-896.
5. Fimiani M, Rubegni P, DiRenzo M, et al. Photopheresis restores TH1/TH2 imbalance in patients with mycosis fungoides. J Eur Acad Dermatol Vencreol 1997; 9(1): S221-P295.
6. Bladon J, Taylor P. Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous t-cell lymphoma and graft-versus-host disease patients. Br J of Hematol 1999; 107: 707-711.
7. Saed G, Fivenson D. Augmentation of TH-1 cytokines in the peripheral blood of Sezary syndrome patients after treatment with extracorporeal photophoresis. J of Investigative Dermatology 1994; 694: abstract.
8. Rook A, Suchin K, Kao D, et al. Photopheresis: Clinical applications and mechanism of action. Soc Invest Dermatol 1999; 4(1): 85-90.
9. Bisaccia E, Berger C, klainer AS. Extracorporeal photopheresis in the treatment of AIDS-related complex: A pilot study. Ann Inter Med 1990; 13(4).
10. Bisaccia E, Berger C, DiSpaltro F, Klainer AS. Extracorporeal photopheresis in the treatmentof AIDS-related complex: Extended trial. J AIDS 1993; 6(5): 386-392.
11. Edelson R, Perez M, Heald P, Berger C. Extracroporeal photochemotherapy. Biologic Therapy of Cancer Updates, 1994; 4(5): 1-12.
12. Richter AM, StemBerg ED, Dolphin D, Levy JG. Characterization of benzoporphyrin derivative, a new photosensitizer. Adv. Photochemotherapy 1988; 997: 132-138.
13. North J, Neyndorff H, Levy JG. Photosensitizers as virucidal agents. J Photochem Photobiol 1993; 17(2): 99-108.
14. North J, Copombs R, Levy J. Photodynamic inactivations of free and cell-associated HIV-1 using the photosensitizer, Benzoporphyrin Derivative. J AIDS 19947: 891-998.
15. Jamieson CHM, McDonald WN, Levy JG. Preferential up-take of benzoporphyrin derivative by leukemic versus normal cells. Leuk Res 1990; 14: 209-219.
16. Vallat VP, Gilleaudeau P, Battat L, et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 1994; 180: 283-296.
17. Simkin G, King DE, Levy JG, Chan AH, Hunt DWC. Inhibition of contact hypersensitivity with different analogs of Benzoporphyrin derivative. Immunopharmacology 1997; 37: 221-230.
18. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumor immunity. Nat Rev Cancer 2006; 6: 535-545.
19. Kabingu E, Vaughan L, Owczarczak B, Ramsey KD, Gollnick SO. CD8+ T cell-mediated control of distant tumors following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cells. Br J Cancer 2007; In Press.
20. Amin RM, Dean MT, Zaumetzer LE, Poiesz BJ. Virucidal efficacy of various lens cleaning and disinfecting solutions on HIV-1 contaminated contact lenses. AIDS Res Hum Retroviruses 1991; 7: 403-408.
21. Zhang H, Zhang Y, Spicer TP, Abbott LZ, Abbott M, Poiesz BJ. Reverse transcription takes place within extracellular HIV-1 virons: potential biological significance. AIDS Res Hum Retroviruses 1993; 9: 1287-1296.
22. Derby E, Reddy V, Baseler M, Malyguine A. Flow cytometric assay for the simultaneous analysis of cell-mediated cytotoxicity and effecter cell phenotype. Biotechniques 2001; 31: 660-665.
23. Kung PC, Berger CL, Goldstein G, LoGerto P, Edelson RL. Cutaneous T-cell lymphoma: characterization by monoclonal antibodies. Blood 1981; 57: 261-266.
24. Kepner JL, Robinson DH. A distribution-free rank test for ordered alternatives in randomized complete block designs. J Am Stat Assoc 1984; 79(385): 212-217.
25. Hollander M, Wolfe DA. Nonparametric statistical methods. John Wiley and Sons, Inc. 1999; 284-294.
26. Verms I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cell using fluorescein labeled Annexin V. J Immunol Methods 1995; 184: 39-51.
27. Krasagakis K, Zouboulis ChC, Owsianowski M, et al. Remission of scleromyxoederna following treatment with extracorporeal photopheresis. Br J Dermatol 1996; 135: 463-466.
28. Rook A, Suchin K, Kao D, et al. Photopheresis: Clinical applications and mechanism of action. The Society of Investigative Dermatology 1999; 4(1): 85-90.
29. Edelson RL, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987; 316(6): 297-303.
30. Dall'Amico R, Zacchello G. Treatment of graft-versus-host disease with photophersis. Transplantation 1991; 65(9): 1283-1284.
31. Barr M, Meiser B, Eisen H, et al. Photopheresis for the prevention of rejection in cardiac transplantation. N Engl J Med 1998; 339(24): 1744-1751.
32. Enomoto D, Schellekens P, Yong S, Berge I, Mekkes J, Bos J. Extracorporeal photochemotherapy (photopheresis) induces apoptosis in lymphocytes: A possible mechanism of action of PUVA therapy. Photochem Photobiol 1997; 65(1): 177-180.
33. Alcindor T, Gorgun G, Miller KB, et al. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-bost disease. Blood 2001; 98(5): 1622-1625.
34. Romagnani S. Biology of human TH1 and TH2 cells. J Clin Immunol 1995; 15: 121-129.
35. del Prete G, de Carli M, Almerigogna F, et al. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993; 150: 353-360.
36. Clerici M, Balotta C, Meroni L, et al. Type 1 cytokine production and low prevalence of viral isolation correlate with long-term non-progression in HIV ihfection. AIDS Res Hum Retroviruses 1996; 12(11): 1053-1061.
37. Heald P, Kim HY, Perez M, Edelson R, Berger C. T-cell responses in photoimmune therapy. J Clin Apheresis 1994; 10: 144-149.
38. Barr ML. Immunomodulation in transplantation with photopheresis. Artif Org 1996; 20: 971-973.
39. Walker BD, Chakrabarti S, Moss B, et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987; 328: 345-348.
40. Plata F, Autran B, Martin LP, et al. AIDS virus specific cytotoxic T lymphocytes in lung disorders. Nature 1987; 328: 348-351.
41. Ogg GS, et al. Quantification of HIV-1 specific cytotoxic T lymphocytes and plasma viral RNA load. Science 1999; 279: 857-860.
42. Wanatabe M, Ringler DJ, Fultz PN, et al. A chimpanzee-passaged human immunodeficiency virus isolate is cytopathic for chimpanzee cells but does not induce disease. J Virol 1991; 65: 3344-3348.
43. Heeney J, Boggers W, Buijs L, et al. Immune strategies utilized by lentivirus-infected chimpanzees to resist progression to AIDS. Immunol Lett 1996; 51: 45-52.